SUBSEQUENT EVENTS |
12 Months Ended |
|---|---|
Dec. 31, 2022 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENTS | SUBSEQUENT EVENTS On February 15, 2023, the Company received $1.5 million from the Cancer Prevention and Research Institute of Texas. The payment is part of a non-dilutive grant of approximately $16.1 million awarded to support operations and development of the Company's drug candidate seclidemstat for the treatment of Ewing sarcoma. The $1.5 million payment brings the Company's cumulative disbursement from CPRIT to approximately $16.0 million. From January 27, 2023 through March 24, 2023, the Company sold 142,499 shares of its common shares with gross proceeds of approximately $0.4 million pursuant to its at the-market equity offering program.
|